Wearable Knee-Resistance Robot Boosts Function in Children with Spinal Muscular Atrophy

A lightweight (under 1 kg) wearable robot that delivers isokinetic knee-extension resistance was tested in six children (ages 6–10) with type 2 spinal muscular atrophy (SMA). After 30 sessions over six weeks, participants showed measurable gains in standing ability, quadriceps size, and knee-extension force.

Nature

SMA is an inherited motor-neuron disease caused by loss-of-function mutations in the SMN1 gene, affecting roughly 1 in 10,000 births. Gene-therapy approaches that augment SMN1 or SMN2 have transformed survival but do not restore muscle that has already atrophied. Conventional physiotherapy yields modest gains, prompting researchers to explore high-intensity, device-assisted rehabilitation.

Nature

The trial was led by bioengineers Tony Shu (Massachusetts Institute of Technology) and Yanggang Feng (Beihang University, China), with contributions from Elvira Pirondini (University of Pittsburgh). All six participants were receiving approved gene therapy and had previously engaged in standard physical rehabilitation without notable functional improvement. The robot’s resistance was gamified, displaying a virtual ball-kicking task to encourage engagement.

Nature

• Quadriceps cross-sectional area: increased by ~20 % (MRI).

Nature

• Knee-extension torque: more than doubled.

Nature

• Standing transition angle: improved from 111° to 104°.

Nature

• Session count: 30 sessions, each >=60 leg movements, over six weeks.

Nature

• Functional outcome: all children could rise from a lower-sitting position, a task they could not perform at baseline.

Nature

The device’s portability makes it suitable for home use, potentially extending intensive rehabilitation beyond clinic visits. By pairing gene therapy with targeted muscle-building exercise, the approach may address a critical gap in SMA care—restoring lost muscle mass and strength.

Nature

Researchers reported that parents observed easier daily movements such as rolling out of bed after training. The team highlighted the “dramatic growth in biomechanical indicators” and noted that the robot’s home-friendly design could facilitate broader clinical adoption. Pirondini emphasized the clinical relevance while cautioning that it remains unclear whether the robot offers advantages over other high-intensity exercise modalities. Hnat praised the comprehensive assessment battery, noting that multiple objective measures corroborated functional gains.

Nature

Pirondini’s comment underscores a key limitation: the study does not establish whether similar outcomes could be achieved with conventional high-intensity exercises, leaving the robot’s unique contribution uncertain.

Nature

The investigation involved only six participants and lacked a control group receiving alternative intensive training, limiting the ability to generalize findings or isolate the robot’s effect. Long-term durability of the gains was not reported.

Nature

• “At home, when their children are trying to roll out of bed or adjust their bodies in certain ways, parents notice that it’s become a lot easier because of the training regimen,” — Tony Shu, Bioengineer, MIT

Nature

• “The dramatic growth in biomechanical indicators and the synergistic changes in the neuromuscular system absolutely shocked us,” — Yanggang Feng, Bioengineer, Beihang University

Nature

• “The portable nature of the device makes it ideal for home settings,” — Yanggang Feng

Nature

• “It’s a very important piece of work that gives important information to the clinic,” — Elvira Pirondini, Bioengineer, University of Pittsburgh

Nature

• “It was nice that they looked at a lot of measures,” — Sandra Hnat, Bioengineer, Case Western Reserve University

Nature

The authors plan larger, controlled trials to compare the robot with other intensive rehabilitation protocols and to assess the longevity of functional improvements.

Nature